Takeda as a World-Class Partner

International strategic products

Takeda's drugs, including the 4 international strategic products^[*], which Takeda created through proprietary research efforts, have gained high repute throughout the world. They are sold today in 70 countries, and their contribution to medical service providers as well as patients and their families is reflected by the increase in sales.

[*] Leuplin (generic name: Leuprorelin acetate), a treatment for prostate cancer and endometriosis; Takepron (generic name: Lansoprazole), a treatment for peptic ulcer; Blopress (generic name: Candesartan cilexetil), an anti-hypertensive agent; and Actos (generic name: pioglitazone hydrochloride), an antidiabetic agent.

Also, in 2006, Takeda launched Rozerem (ramelteon) in the US market as an achievement of our original research efforts. Because of no drug abuse or dependence in Rozerem, it has been the first non-scheduled drug for insomnia without the regulation of the Drug Enforcement Administration, USA. We aim to market it globally.

Presence in Japan and the world

Takeda is Japan's largest pharmaceutical company. It ranks 16th in sales in the world (2006) and is one of the major global pharmaceutical companies.
Its sales bases are not limited to those in Japan. It has a 100% subsidiary in the US (TPNA), and has established an independent sales organizations in European countries (Germany, France, Italy, the United Kingdom, Switzerland, and Austria). In Asia other than Japan, also, it has sales bases in the following countries, China, Taiwan, Indonesia, Thailand, and the Philippines while it also employs the joint venture system excluding Taiwan.

Global research and development system

Research and development bases have spread to 4 regions: Japan, the United States, Europe, and Asia. At 5 research bases, i.e., Osaka and Tsukuba in Japan, San Diego in the US, Cambridge in the UK, and Singapore, Takeda is endeavoring to create epoch-making new drugs that will follow its 4 international strategic products.
It also has 3 development bases in Osaka, Chicago, and London. The fact that Rozerem, Amitiza (generic name: lubiprostone), a treatment for chronic idiopathic constipation, and Duetact, a treatment for diabetes mellitus, which was marketed in the US in 2005-2006, were all approved within 10 months after application is evidence of the strong drug-developing capability of the Takeda Group.